Comparative Pharmacology
Head-to-head clinical analysis: FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE versus ZUTRIPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE versus ZUTRIPRO.
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE vs ZUTRIPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid with anti-inflammatory activity; salmeterol xinafoate is a selective long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle.
Combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 adrenergic agonist); ipratropium inhibits muscarinic receptors reducing bronchoconstriction, albuterol stimulates beta-2 receptors causing bronchodilation.
One inhalation (100 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart. For patients not adequately controlled on lower doses, may increase to one inhalation of 250/50 or 500/50 twice daily.
2 inhalations (90 mcg each) orally via inhalation twice daily, with a maximum of 2 inhalations per dose.
None Documented
None Documented
Fluticasone propionate: terminal half-life approximately 7.8 hours (range 6-10 hours) after inhalation; clinically supports twice-daily dosing. Salmeterol: terminal half-life approximately 5.5 hours (range 3-12 hours) after inhalation.
Terminal elimination half-life is 8-12 hours; clinically, steady-state is achieved within 2-3 days.
Fluticasone propionate is eliminated primarily via hepatic metabolism and fecal excretion; <5% excreted renally. Salmeterol xinafoate is predominantly eliminated via hepatic metabolism with ~25% excreted in feces and <10% in urine as unchanged drug.
Primarily renal as unchanged drug (60-70%) and metabolites (20-30%); biliary/fecal elimination accounts for 10-20%.
Category A/B
Category C
LABA
Combined Bronchodilator (LAMA/LABA/ICS)